Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Holdings Boosted by PDT Partners LLC

PDT Partners LLC boosted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 166.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 107,159 shares of the company’s stock after acquiring an additional 66,868 shares during the period. PDT Partners LLC owned about 0.15% of Zentalis Pharmaceuticals worth $394,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ZNTL. GSA Capital Partners LLP increased its stake in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares during the period. Decheng Capital LLC increased its stake in shares of Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after purchasing an additional 970,859 shares during the period. XTX Topco Ltd increased its stake in shares of Zentalis Pharmaceuticals by 1,581.9% in the second quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after purchasing an additional 167,854 shares during the period. Verition Fund Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares during the period.

Analyst Ratings Changes

Several equities research analysts have commented on ZNTL shares. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $3.36 on Wednesday. Zentalis Pharmaceuticals, Inc. has a 1-year low of $2.66 and a 1-year high of $18.07. The company has a 50 day moving average price of $3.36 and a 200 day moving average price of $4.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. Sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.